Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.38 |
| ▸ | TSHR | P16473 | 7/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10128467 | 0.94 | USP2 (0.49) | USP2CYP1A2CYP3A4TSHRCYP2D6 | |
| SCHEMBL10128592 | 0.92 | CYP2D6 (0.38) | USP2CYP1A2CYP3A4TSHRCYP2D6 | |
| SCHEMBL10168674 | 0.89 | CYP3A4 (0.41) | USP2CYP1A2CYP3A4TSHRCYP2D6 | |
| SCHEMBL14768453 | 0.86 | USP2 (0.38) | USP2CYP1A2CYP3A4TSHRCYP2D6 | |
| SCHEMBL10111444 | 0.86 | CYP2D6 (0.39) | USP2CYP1A2CYP3A4TSHRCYP2D6 | |
| SCHEMBL18705142 | 0.85 | USP2 (0.44) | USP2CYP1A2CYP3A4TSHRCYP2D6 | |
| SCHEMBL25571376 | 0.84 | CYP2D6 (0.36) | USP2CYP1A2CYP3A4TSHRCYP2D6 | |
| SCHEMBL10094137 | 0.82 | CYP3A4 (0.34) | USP2CYP1A2CYP3A4TSHRCYP2D6 | |
| SCHEMBL24576857 | 0.81 | CYP2D6 (0.39) | USP2CYP1A2CYP3A4TSHRCYP2D6 | |
| SCHEMBL14768435 | 0.81 | CYP2D6 (0.39) | USP2CYP1A2CYP3A4TSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065883-A1 | Triazolo [4, 5- B] Pyridin Derivatives | Centro Nacional de Investigaceiones Oncologicas (CNIO) (ES) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065883-A1 | Triazolo [4, 5- B] Pyridin Derivatives | PIM1, PIM3, PIM2 | USP2 4138/4885CYP1A2 1252/4885CYP3A4 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.